#biosimilars
Emcure doubling down on biosimilars pipeline: MD Satish Mehta
Emcure currently has six biosimilars in the market, launched through its subsidiary Gennova Biopharmaceuticals. While it has developed these in-house so far, the drugmaker will also scout for partners with products not in their pipeline, for commercialisation…
Rituximab Biosimilars Market Trastuzumab Biosimilars Market Research Analysis Report 2026: $6.2 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
Key opportunities in the rituximab biosimilars market include the launch of new biosimilar formulations, expansion of subcutaneous delivery options, and increasing adoption in emerging markets. Rising prevalence of non-Hodgkin's lymphoma and autoimmune diseas…
Trastuzumab Biosimilars Market Analysis Report 2026: $24.48 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
The trastuzumab biosimilars market is expanding due to increasing cancer prevalence, loss of patent exclusivity, and cost-effective therapies. Opportunities abound in biosimilar expansions, physician confidence, untapped regional markets, and favorable reimbu…
Sun Pharma shares rally 9% in two days after $12-bn Organon deal. Here's what Morgan Stanley, other brokerages say
Sun Pharmaceutical Industries' shares surged nearly 9% after announcing the $11.75 billion acquisition of Organon & Co., a global leader in women's health. The deal diversifies Sun Pharma's portfolio into women's health and biosimilars, with analysts from Mor…
Why Sun Pharma’s massive Organon buyout is winning over investors where Lupin, Biocon failed
Sun Pharma’s acquisition of Organon marks a pivot toward biosimilars, utilizing a cheap valuation and strong cash reserves to avoid the chronic post-merger stock slumps seen by Indian rivals.